Kalvista Pharmaceuticals Stock Investor Sentiment

KALV Stock  USD 11.40  0.71  6.64%   
Slightly above 51% of Kalvista Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Kalvista Pharmaceuticals suggests that many traders are impartial. Kalvista Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Kalvista Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  

Kalvista Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Kalvista Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
54.4%
55.6%
53.9%
60.5%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at www.macroaxis.com         
Acquisition by Audhya Paul K. of 18531 shares of Kalvista Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over three months ago at www.macroaxis.com         
Disposition of 8077 shares by Audhya Paul K. of Kalvista Pharmaceuticals at 9.2566 subject to Rule 1...
Macroaxis News
over three months ago at www.macroaxis.com         
Disposition of 12084 shares by Audhya Paul K. of Kalvista Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over three months ago at gurufocus.com         
Insight into TANG CAPITAL MANAGEMENT LLCs Strategic Acquisition of KalVista Pharmaceuticals ...
Gurufocus Stories at Macroaxis
over three months ago at gurufocus.com         
Vestal Point Capital, LP Increases Stake in KalVista Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over three months ago at gurufocus.com         
Capital World Investors Expands Stake in KalVista Pharmaceuticals
Gurufocus Stories at Macroaxis
over three months ago at gurufocus.com         
Vanguard Group Incs Strategic Acquisition in KalVista Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over three months ago at finance.yahoo.com         
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over three months ago at businesswire.com         
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
businesswire News
over three months ago at finance.yahoo.com         
KalVista Pharmaceuticals Announces Pricing of a 55 Million Underwritten Offering of Common Stock and...
Yahoo News
over three months ago at businesswire.com         
KalVista Pharmaceuticals Announces Pricing of a 55 Million Underwritten Offering of Common Stock and...
businesswire News
over three months ago at businesswire.com         
KalVista Pharmaceuticals Announces Pricing of a 55 Million Underwritten Offering of Common Stock and...
businesswire News
over three months ago at finance.yahoo.com         
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of...
Yahoo News
over three months ago at seekingalpha.com         
KalVista prices 55M stock offering
seekingalpha News
over three months ago at finance.yahoo.com         
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asth...
Yahoo News
Far too much social signal, news, headlines, and media speculation about Kalvista Pharmaceuticals that are available to investors today. That information is available publicly through Kalvista media outlets and privately through word of mouth or via Kalvista internal channels. However, regardless of the origin, that massive amount of Kalvista data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kalvista Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kalvista Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kalvista Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kalvista Pharmaceuticals alpha.

Kalvista Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.15123456789101112131415161718Dec2025Feb -20-15-10-5051015
JavaScript chart by amCharts 3.21.15Kalvista Pharmaceuticals Kalvista Pharmaceuticals Dividend Benchmark Dow Jones Industrial
       Timeline  
1
Acquisition by Audhya Paul K. of 5000 shares of Kalvista Pharmaceuticals subject to Rule 16b-3
11/29/2024
2
Disposition of 15625 shares by Benjamin Palleiko of Kalvista Pharmaceuticals subject to Rule 16b-3
12/06/2024
3
Disposition of 7627 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 9.75 subject to Rule 16b-3
12/09/2024
4
KalVista Appoints Jeb Ledell as Chief Operating Officer
12/16/2024
5
Insider Trading
01/30/2025
6
Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 11754 shares of Kalvista Pharmaceuticals at 8.89 subject to Rule 16b-3
02/03/2025
7
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
02/04/2025
8
Venrock Healthcare Capital Par Purchases 43,707 Shares of KalVista Pharmaceuticals, Inc. Stock
02/06/2025
9
Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 73649 shares of Kalvista Pharmaceuticals at 9.29 subject to Rule 16b-3
02/07/2025
10
KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma Immunology 2025 Annual Meeting
02/10/2025
11
Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 26703 shares of Kalvista Pharmaceuticals at 9.18 subject to Rule 16b-3
02/11/2025
12
Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 100000 shares of Kalvista Pharmaceuticals at 9.23 subject to Rule 16b-3
02/12/2025
13
Disposition of 2419 shares by Benjamin Palleiko of Kalvista Pharmaceuticals subject to Rule 16b-3
02/14/2025
14
Disposition of 5104 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 9.8242 subject to Rule 16b-3
02/18/2025
15
Acquisition by Christopher Yea of 4204 shares of Kalvista Pharmaceuticals subject to Rule 16b-3
02/19/2025
16
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma Immunology 2025 Annual Meeting
02/21/2025
17
Disposition of 1918 shares by Christopher Yea of Kalvista Pharmaceuticals at 10.02 subject to Rule 16b-3
02/24/2025
18
KalVista Pharmaceuticals, Inc. Insider Paul K. Audhya Sells 2,394 Shares of Stock
02/26/2025

Additional Tools for Kalvista Stock Analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.